Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06611436 · ClinicalTrials.gov registry record · Phase 1
BeCoMe-9: A Clinical Study of BE-101 for the Treatment of Adults With Moderately Severe or Severe Hemophilia B
A Phase 1 study of Hemophilia B and Hemophilia B, Moderately Severe or Severe, sponsored by Be Biopharma.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 24
- Enrollment target
- 4
- Study locations
NCT06611436 is a Phase 1 study of Hemophilia B and Hemophilia B, Moderately Severe or Severe that is actively recruiting participants, run by Be Biopharma. The registered enrollment target is 24 participants, below the 95-participant average among 20 other Hemophilia B trials with a reported enrollment target (75% lower). The trial reports 4 study locations across 4 states.
The verdict
NCT06611436, a Phase 1 study of Hemophilia B and Hemophilia B, Moderately Severe or Severe, is actively recruiting participants, sponsored by Be Biopharma.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 24 participants
- Enrollment target
- 4
- Study locations
Study Summary
The BeCoMe-9 Study (BE-101-01) is a Phase 1/2, first in human, multi-center, open-label, dose-escalation study to evaluate the safety and clinical activity of a single intravenous (IV) dose of BE-101 in adults with moderately severe or severe Hemophilia B. Once infused, BE-101 is designed to engraft and continuously secrete FIX into the circulation to restore clinically meaningful levels of active FIX. BE-101 is an autologous (person's own cells) B Cell Medicine (BCM) which uses CRISPR/Cas9 gene editing to precisely insert human FIX gene into those cells.
Conditions Studied
Interventions
- DRUG BE-101
Study Locations (4)
California
- University of California, Davis - Davis
Michigan
- University of Michigan - Ann Arbor
Minnesota
- University of Minnesota - Minneapolis
Washington
- Washington Center for Bleeding Disorders - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2024-12-04 |
| Est. Completion | 2027-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06611436
The ClinicalTrials.gov registry entry for NCT06611436 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 95-participant average among 20 other Hemophilia B trials with a reported enrollment target (75% lower). The listed sponsor is Be Biopharma, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Hemophilia B appearing as the primary indexed condition, and to 1 intervention - of which BE-101 is the first listed.
NCT06611436 reports 4 study locations spanning 4 distinct geographic areas - top geographies include California, Michigan, Minnesota.
Frequently Asked Questions
What is clinical trial NCT06611436 about?
NCT06611436 is a clinical study titled "BeCoMe-9: A Clinical Study of BE-101 for the Treatment of Adults With Moderately Severe or Severe Hemophilia B". The BeCoMe-9 Study (BE-101-01) is a Phase 1/2, first in human, multi-center, open-label, dose-escalation study to evaluate the safety and clinical activity of a single intravenous (IV) dose of BE-101 in adults with moderately severe or severe Hemophilia B. Once infused, BE-101 is designed to engraft...
What is the current status of trial NCT06611436?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2024-12-04. Estimated completion is 2027-07.
What conditions does trial NCT06611436 study?
This clinical trial studies the following conditions: Hemophilia B, Hemophilia B, Moderately Severe or Severe.
What interventions are being tested in trial NCT06611436?
The interventions under investigation include: BE-101 (DRUG).
Who is sponsoring clinical trial NCT06611436?
This trial is sponsored by Be Biopharma, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06611436 being conducted?
This trial has 4 study locations across California, Michigan, Minnesota, Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hemophilia B
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Investigate the Safety and Effectiveness of a Coagulation Factor IX Gene Insertion Therapy (REGV131-LNP1265) in Pediatric, Adolescent and Adult Participants With Hemophilia B
RECRUITING · Phase 1
-
A Study of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SR604 in Two Participants Groups (Part A: Healthy Participants, and Part B: Participants With Hemophilia A or Hemophilia B or Factor VII Deficiency)
RECRUITING · Phase 1
-
Dose-Escalation Study Of A Self Complementary Adeno-Associated Viral Vector For Gene Transfer in Hemophilia B
ACTIVE NOT RECRUITING · Phase 1
-
Open-Label Single Ascending Dose of Adeno-associated Virus Serotype 8 Factor IX Gene Therapy in Adults With Hemophilia B
ACTIVE NOT RECRUITING · Phase 1
-
Phase 3, Open-label, Single-dose Study of CSL222 in Adolescent Male Subjects (≥ 12 to < 18 Years of Age) With Severe or Moderately Severe Hemophilia B
RECRUITING · Phase 3
-
A Clinical Trial of Study Medicine (Marstacimab) in Pediatric Patients With Hemophilia A or Hemophilia B
RECRUITING · Phase 3
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.